B.Riley Downgrades Dicerna Pharmaceuticals (DRNA) to Neutral, Following Earnings
Tweet Send to a Friend
B.Riley analyst Mayank Mamtani downgraded Dicerna Pharmaceuticals (NASDAQ: DRNA) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
